ArticleDiscover nano2025
Doxorubicin delivery of green-synthesized gold nanoparticles to MDA-MB-231 cells and collagen type II identification from yellow nose skate cartilage.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Doxorubicin-Loaded Poly(Substituted Glycolide)-Based Nanoparticles for Long-Term Storage.ACS omega · 2026Article
- Chondroitin Sulfate-Based Nanoplatforms: Advances and Challenges for Cancer Therapy.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Upcycling and green synthesis strategies have been applied for the synthesis of gold nanoparticles (AuNPs) using yellow nose skate (Dipturus chilensis) cartilage extract as a reducing and stabilizing agent (skAu). Doxorubin (DOX) was loaded onto the skAu, and the average size of the DOX-loaded AuNPs (c-skAuD) was measured to be 14.6 ± 0.5 nm by high-resolution transmission electron microscopy. Reaction parameters such as reaction time and DOX concentration were optimized for preparing c-skAuD. DOX was successfully loaded, as confirmed by the FT-IR results. In addition, FT-IR characterization revealed that chondroitin sulfate and collagen in the extract were involved in the synthesis of skAu. Although c-skAuD is cytotoxic to four different types of cancer cells (AGS, HeLa, A549 and MDA-MB-231), their cytotoxic effects were greatest on MDA-MB-231 cells. Analyzing cytotoxicity onto MDA-MB-231 cells revealed that c-skAuD had the greatest cytotoxicity, followed by a positive control (c-citAuD) and DOX. Furthermore, this cytotoxicity was dependent on the incubation time and DOX concentration. Cellular uptake of Au by inductively coupled plasma‒mass spectrometry demonstrated that compared with AGS cells (15.1%), MDA-MB-231 cells showed approximately two-fold greater Au uptake (29.9%) of c-skAuD. However, the Au uptake of the positive control (c-citAuD) did not significantly differ between the MDA-MB-231 and AGS cells. Moreover, collagen type II was identified in the extract by peptide analysis using LC‒ESI‒MS/MS. To the best of our knowledge, we are the first to report collagen type II in D. chilensis cartilage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.